Anteris Technologies Global (NASDAQ:AVR) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Anteris Technologies Global (NASDAQ:AVR) issued its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03, FiscalAI reports. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $2.75 million.

Anteris Technologies Global Stock Down 0.8%

AVR traded down $0.05 during midday trading on Tuesday, hitting $5.89. 778,730 shares of the company were exchanged, compared to its average volume of 1,161,049. The firm’s 50 day moving average price is $7.18 and its 200-day moving average price is $7.39. Anteris Technologies Global has a 1-year low of $3.30 and a 1-year high of $11.06. The firm has a market capitalization of $574.04 million, a P/E ratio of -3.02 and a beta of 2.02.

Analysts Set New Price Targets

AVR has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of Anteris Technologies Global in a report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Finally, Barclays upgraded shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Anteris Technologies Global currently has a consensus rating of “Hold” and an average price target of $14.00.

Insider Buying and Selling at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd purchased 272,695 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The stock was bought at an average price of $7.18 per share, with a total value of $1,957,950.10. Following the completion of the purchase, the insider owned 6,358,271 shares in the company, valued at approximately $45,652,385.78. This represents a 4.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders bought a total of 1,554,730 shares of company stock valued at $11,694,513 over the last ninety days. Corporate insiders own 4.50% of the company’s stock.

About Anteris Technologies Global

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.